LT2849798T - Oligonukleotido chelato komplekso ir polipeptido kompozicijos ir būdai - Google Patents

Oligonukleotido chelato komplekso ir polipeptido kompozicijos ir būdai

Info

Publication number
LT2849798T
LT2849798T LTEP13791618.5T LT13791618T LT2849798T LT 2849798 T LT2849798 T LT 2849798T LT 13791618 T LT13791618 T LT 13791618T LT 2849798 T LT2849798 T LT 2849798T
Authority
LT
Lithuania
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
oligonucleotide
Prior art date
Application number
LTEP13791618.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2849798(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of LT2849798T publication Critical patent/LT2849798T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
LTEP13791618.5T 2012-05-18 2013-05-17 Oligonukleotido chelato komplekso ir polipeptido kompozicijos ir būdai LT2849798T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
LT2849798T true LT2849798T (lt) 2021-08-10

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13791618.5T LT2849798T (lt) 2012-05-18 2013-05-17 Oligonukleotido chelato komplekso ir polipeptido kompozicijos ir būdai

Country Status (34)

Country Link
US (1) US9492506B2 (OSRAM)
EP (1) EP2849798B1 (OSRAM)
JP (1) JP2015517504A (OSRAM)
KR (1) KR102068109B1 (OSRAM)
CN (1) CN104349793B (OSRAM)
AU (1) AU2013262416B2 (OSRAM)
BR (1) BR112014028654A2 (OSRAM)
CA (1) CA2873529C (OSRAM)
CL (1) CL2014003134A1 (OSRAM)
CO (1) CO7131387A2 (OSRAM)
CR (1) CR20140527A (OSRAM)
CY (1) CY1124345T1 (OSRAM)
DK (1) DK2849798T3 (OSRAM)
DO (1) DOP2014000264A (OSRAM)
EA (1) EA035967B1 (OSRAM)
EC (1) ECSP14027694A (OSRAM)
ES (1) ES2873844T3 (OSRAM)
HR (1) HRP20210840T1 (OSRAM)
HU (1) HUE054875T2 (OSRAM)
IL (1) IL235548B (OSRAM)
LT (1) LT2849798T (OSRAM)
MX (1) MX346239B (OSRAM)
MY (1) MY168778A (OSRAM)
NZ (1) NZ703095A (OSRAM)
PH (1) PH12014502551B1 (OSRAM)
PL (1) PL2849798T3 (OSRAM)
PT (1) PT2849798T (OSRAM)
RS (1) RS62030B1 (OSRAM)
SG (1) SG11201407599SA (OSRAM)
SI (1) SI2849798T1 (OSRAM)
SM (1) SMT202100319T1 (OSRAM)
TW (1) TWI635864B (OSRAM)
WO (1) WO2013170386A1 (OSRAM)
ZA (1) ZA201408674B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
PT3166615T (pt) * 2014-07-10 2023-11-13 Replicor Inc Polímeros de ácidos nucleicos fosforotioados quelados para utilização em combinação com um inibidor da polimerase de hbv para o tratamento de infeções pelo vírus da hepatite b e hepatite d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010138806A2 (en) * 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8598334B2 (en) * 2009-10-16 2013-12-03 Glaxo Group Limited HBV antisense inhibitors
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
TWI635864B (zh) 2018-09-21
KR20150013309A (ko) 2015-02-04
CA2873529C (en) 2020-08-18
HUE054875T2 (hu) 2021-10-28
ECSP14027694A (es) 2015-12-31
DK2849798T3 (da) 2021-05-31
JP2015517504A (ja) 2015-06-22
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
AU2013262416B2 (en) 2017-05-11
EP2849798A4 (en) 2016-03-09
CN104349793A (zh) 2015-02-11
EP2849798A1 (en) 2015-03-25
WO2013170386A1 (en) 2013-11-21
CN104349793B (zh) 2017-11-10
CL2014003134A1 (es) 2015-02-13
EA201401278A1 (ru) 2015-04-30
AU2013262416A1 (en) 2014-12-18
US9492506B2 (en) 2016-11-15
CY1124345T1 (el) 2022-07-22
ES2873844T3 (es) 2021-11-04
SG11201407599SA (en) 2014-12-30
HK1204279A1 (en) 2015-11-13
HRP20210840T1 (hr) 2021-08-06
MY168778A (en) 2018-12-04
CO7131387A2 (es) 2014-12-01
ZA201408674B (en) 2016-01-27
MX2014014021A (es) 2015-02-10
SI2849798T1 (sl) 2021-08-31
DOP2014000264A (es) 2015-01-31
PT2849798T (pt) 2021-05-18
CR20140527A (es) 2014-12-15
CA2873529A1 (en) 2013-11-21
PH12014502551B1 (en) 2019-10-11
US20130309201A1 (en) 2013-11-21
MX346239B (es) 2017-03-13
EP2849798B1 (en) 2021-04-07
NZ703095A (en) 2016-07-29
EA035967B1 (ru) 2020-09-07
PH12014502551A1 (en) 2015-01-21
IL235548B (en) 2019-07-31
KR102068109B1 (ko) 2020-01-21
TW201408308A (zh) 2014-03-01
PL2849798T3 (pl) 2021-10-18
SMT202100319T1 (it) 2021-09-14
RS62030B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
BR112015003227A2 (pt) processos de clicoconjugação e composições
GB2500274B (en) Fan
LT3495392T (lt) Anti-cgrp kompozicijos ir jų panaudojimas
DE112013000343A5 (de) Grill
DK3590358T3 (da) Næringsmiddelsammensætning
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
LT2704703T (lt) Transderminės ibuprofeno kompozicijos ir jų naudojimo būdai
JP2012236821A5 (ja) 有機金属錯体
BR112014032798A2 (pt) composição
EP2846045A4 (en) FAN
ME03413B (me) Kompozicije које sadrže peg i askorbat
LT2849798T (lt) Oligonukleotido chelato komplekso ir polipeptido kompozicijos ir būdai
DK2868318T4 (da) Injicerbar formulering
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
BR112014032712A2 (pt) composição
BR112015011095A2 (pt) aparelho
EP2861718A4 (en) COMPOSITIONS WITH CHALKOGENIDES AND RELATED METHODS
DK2811828T3 (da) Adjuvanssammensætninger
EP2837670A4 (en) Fluorobiphenyl-containing composition
DK2872828T3 (da) Gasvarmeapparat
GB2502389B (en) Hood
EP2894308A4 (en) EXHAUST MIXER
DK2800573T3 (da) Oftalmologisk sammensætning